BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15702447)

  • 21. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
    Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
    Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
    Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).
    Pectasides D; Papaxoinis G; Fountzilas G; Aravantinos G; Bamias A; Pavlidis N; Kalofonos HP; Timotheadou E; Samantas E; Briasoulis E; Skarlos DV; Economopoulos T; Dimopoulos MA;
    Anticancer Res; 2009 Feb; 29(2):745-51. PubMed ID: 19331231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of hospital volume on local recurrence and survival in a population sample of rectal cancer patients.
    Engel J; Kerr J; Eckel R; Günther B; Heiss M; Heitland W; Siewert JR; Jauch KW; Hölzel D
    Eur J Surg Oncol; 2005 Jun; 31(5):512-20. PubMed ID: 15878259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ErbB-3 predicts survival in ovarian cancer.
    Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
    J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
    J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
    Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
    Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
    Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
    J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
    Cliby WA; Aletti GD; Wilson TO; Podratz KC
    Gynecol Oncol; 2006 Dec; 103(3):797-801. PubMed ID: 17052746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and outcomes in patients with advanced rectal cancer: a national prospective cohort study.
    Sigurdsson HK; Körner H; Dahl O; Skarstein A; Søreide JA;
    Dis Colon Rectum; 2007 Mar; 50(3):285-91. PubMed ID: 17235720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.
    Aletti GD; Dowdy SC; Podratz KC; Cliby WA
    Am J Obstet Gynecol; 2007 Dec; 197(6):676.e1-7. PubMed ID: 18060979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.